• Alex Marion

    Member
    September 16, 2024 at 5:10 am

    https://www.globenewswire.com/news-release/2024/09/16/2946446/0/en/Boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-III-FIBRONEER-IPF-study.html

    • Charlene

      Member
      September 19, 2024 at 8:40 am

      Thanks for sharing the link to more information Alex-Marion! I’m curious to see what happens with the development of this drug and from patients who speak with their physicians about it.

      Char.

  • Alex Marion

    Member
    September 16, 2024 at 5:15 am

    Apparently, it will be a new drug in the market with better results, in 2025/6

  • Adele Friedman

    Member
    September 17, 2024 at 2:29 pm

    My husband used to work in clinical research for this company, which is privately owned by a German family. He worked in cardiac, not pulmonary, drugs. This drug sounds promising. It should be noted it is for IPF patients, not those whose PF has an identifiable cause, such as my autoimmune disease. Mine is Sjogren’s Syndrome, but other autoimmune diseases and other identifiable causes for PF may lead doctors to try different treatments. Of course, doctors can and do prescribe for “off label” indications if they feel a patient would benefit. I just want to point out, this drug is–for now, at least–only for IPF.

  • momofGracie

    Member
    September 17, 2024 at 5:00 pm

    I have non specific interstitial pneumonia. Do you know if this drug is appropriate for NSIP?

  • Alex Marion

    Member
    September 19, 2024 at 4:17 pm

    Hi Charlene

    I think this will work, otherwise wouldn’t apply to fda .

    I did ask s Dr, in Toronto general back in May this year, and they dodge the question with a maybe answer.

    I also asked for the trial of Bristol Mayer drug, that fir what I read works better and minimum side effect. This trial still going till end 2025.

    Because in 1 year all the patented drugs loose their monopoly, I imagine, they will supply the market with a better one.

    Bi 1015550 realy work well in the 12 weeks phase 2, improved fvc, compared yo placebo.

    https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.facebook.com/TheNewEnglandJournalofMedicine/videos/quick-take-pde4b-inhibitor-for-idiopathic-pulmonary-fibrosis/594517251882750/&ved=2ahUKEwiI8Ki29M-IAxXHg4kEHQveGJkQo7QBegQIDhAF&usg=AOvVaw3cuwlzmj9DOOoTjyFHxhdr

  • Alex Marion

    Member
    September 20, 2024 at 1:35 am

    Somthing more that looks possitive.

    https://6abc.com/temple-lung-center-idiopathic-pulmonary-fibrosis-scar-tissue-breathe/13577878/

  • buckeyegoodguy

    Member
    August 20, 2025 at 1:37 pm

    You really should try Medical Marijuana and CDB together…Cheap $ and I have had IPF for 13 years now and my doc. knows that is why I have made it this long. See my post under treatments or read my profile. God put that plant here and it works…Just saying

  • Thomas

    Member
    August 22, 2025 at 2:32 pm

    My doc just applied for compassionate use of this drug on my behalf. I am late stage IPF and emphysema. Only cohorts of the previous Phase 3 trial are eligible for the latest one.

  • RobJ

    Member
    September 1, 2025 at 1:48 pm

    I hope you can get approval. They should grant approval to anyone in these circumstances to give hope and chances to live

  • Sheila

    Member
    September 2, 2025 at 4:13 pm

    I was in the nerandomilast trial (BI1015550) and after a year my lung function had declined a little, but not much. Then I discovered I was on the placebo. 5 months after starting the real drug, my lung function was more or less back to where it was in 2017, before I had been diagnosed with IPF. So… clearly nerandomilast is not a panacea for everyone but my experience shows that for some, nerandomilast is a total game changer. I really hope it gets FDA approval soon.

Log in to reply.